n Cardiovascular Journal of South Africa - EC approves irbesartan for the treatment of diabetic renal disease : drug trends in cardiology

Volume 13, Issue 4
  • ISSN : 1680-0745



Extracted from text ... EC approves irbesartan for the treatment of diabetic renal disease. BristolMyers Squibb Company (NYSE: BMY) and SanofiSynthelabo (Paris Bourse: Sicovam code 12057) have announced that the European Commission has approved irbesartan (Aprove?/Karve?) in the European Union for a new indication: the treatment of renal disease in people with hypertension and type 2 diabetes mellitus (as part of a antihypertensive drug regimen). Irbesartan is the first blood pressurelowering drug approved across the European Union for treatment of both early and latestage diabetic renal disease in hypertensive type 2 diabetic patients. Irbesartan, an angiotensin II receptor antagonist (AIIRA), is already indicated for ..

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error